Form 4 for BDTX Black Diamond Therapeutics, Inc.
Accepted 2025-01-31 00:00:00 ET · period of report 2025-01-30 · accession 0001415889-25-002494 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-31 | 2025-01-30 | BDTX | Velleca Mark A. | Pres, CEO, Dir | A - Grant | $0.00 | +75.0K | 121.5K | +161% | $0 |
| D | 2025-01-31 | 2025-01-30 | BDTX | Velleca Mark A. | Pres, CEO, Dir | A - Grant | $0.00 | +500.0K | 500.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-30 | A | A | 75,000 | $0.00 | 121,522 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-01-30 | A | A | 500,000 | $0.00 | 500,000 | D | $2.52 · — to 2035-01-29 | 500,000 Common Stock | (F2) 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |